Proteomic blood profiling in mild, severe and critical COVID-19 patients

Abstract The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in most individuals, leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hamel Patel, Nicholas J. Ashton, Richard J. B. Dobson, Lars-Magnus Andersson, Aylin Yilmaz, Kaj Blennow, Magnus Gisslen, Henrik Zetterberg
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/85741894ac0a46b49312bed2836a1782
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85741894ac0a46b49312bed2836a1782
record_format	dspace
spelling	oai:doaj.org-article:85741894ac0a46b49312bed2836a17822021-12-02T17:05:46ZProteomic blood profiling in mild, severe and critical COVID-19 patients10.1038/s41598-021-85877-02045-2322https://doaj.org/article/85741894ac0a46b49312bed2836a17822021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85877-0https://doaj.org/toc/2045-2322Abstract The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in most individuals, leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure and death. This study explores the proteomic differences between mild, severe, and critical COVID-19 positive patients to further understand the disease progression, identify proteins associated with disease severity, and identify potential therapeutic targets. Blood protein profiling was performed on 59 COVID-19 mild (n = 26), severe (n = 9) or critical (n = 24) cases and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology panels. Differential expression analysis was performed within and between disease groups to generate nine different analyses. From the 368 proteins measured per individual, more than 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease severity. The results have been made readily available through an interactive web-based application for instant data exploration and visualization, and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/ . Our results demonstrate that dynamic changes in blood proteins associated with disease severity can potentially be used as early biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets.Hamel PatelNicholas J. AshtonRichard J. B. DobsonLars-Magnus AnderssonAylin YilmazKaj BlennowMagnus GisslenHenrik ZetterbergNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hamel Patel Nicholas J. Ashton Richard J. B. Dobson Lars-Magnus Andersson Aylin Yilmaz Kaj Blennow Magnus Gisslen Henrik Zetterberg Proteomic blood profiling in mild, severe and critical COVID-19 patients
description	Abstract The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in most individuals, leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure and death. This study explores the proteomic differences between mild, severe, and critical COVID-19 positive patients to further understand the disease progression, identify proteins associated with disease severity, and identify potential therapeutic targets. Blood protein profiling was performed on 59 COVID-19 mild (n = 26), severe (n = 9) or critical (n = 24) cases and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology panels. Differential expression analysis was performed within and between disease groups to generate nine different analyses. From the 368 proteins measured per individual, more than 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease severity. The results have been made readily available through an interactive web-based application for instant data exploration and visualization, and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/ . Our results demonstrate that dynamic changes in blood proteins associated with disease severity can potentially be used as early biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets.
format	article
author	Hamel Patel Nicholas J. Ashton Richard J. B. Dobson Lars-Magnus Andersson Aylin Yilmaz Kaj Blennow Magnus Gisslen Henrik Zetterberg
author_facet	Hamel Patel Nicholas J. Ashton Richard J. B. Dobson Lars-Magnus Andersson Aylin Yilmaz Kaj Blennow Magnus Gisslen Henrik Zetterberg
author_sort	Hamel Patel
title	Proteomic blood profiling in mild, severe and critical COVID-19 patients
title_short	Proteomic blood profiling in mild, severe and critical COVID-19 patients
title_full	Proteomic blood profiling in mild, severe and critical COVID-19 patients
title_fullStr	Proteomic blood profiling in mild, severe and critical COVID-19 patients
title_full_unstemmed	Proteomic blood profiling in mild, severe and critical COVID-19 patients
title_sort	proteomic blood profiling in mild, severe and critical covid-19 patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/85741894ac0a46b49312bed2836a1782
work_keys_str_mv	AT hamelpatel proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT nicholasjashton proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT richardjbdobson proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT larsmagnusandersson proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT aylinyilmaz proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT kajblennow proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT magnusgisslen proteomicbloodprofilinginmildsevereandcriticalcovid19patients AT henrikzetterberg proteomicbloodprofilinginmildsevereandcriticalcovid19patients
_version_	1718381800114356224

Proteomic blood profiling in mild, severe and critical COVID-19 patients

Ejemplares similares